Research and Markets: Global Antibody Partnering 2010-2015: Updated Deal Trends, Players and Financials of 3,500 Deal Records

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/mz2tcx/global_antibody) has announced the addition of the "Global Antibody Partnering 2010-2015: Deal trends, players and financials" report to their offering.

The Global Antibody Partnering 2010-2015 report provides an understanding and access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all antibody partnering deals announced since 2010 including financial terms where available including over 3,500 links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Global Antibody Partnering 2010-2015 includes:

  • Trends in antibody dealmaking in the biopharma industry since 2010
  • Analysis of antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 3,500 antibody deal records
  • The leading antibody deals by value since 2010

In Global Antibody Partnering 2010-2015, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

Chapter 3 - Leading antibody deals

Chapter 4 - Big pharma antibody deals

Chapter 5 - Big Biotech antibody deals

Chapter 6 - Antibody dealmaking directory with contract documents

Chapter 7 - Antibody dealmaking by antibody technology type

Chapter 8 - Antibody partnering resource center

For more information visit http://www.researchandmarkets.com/research/mz2tcx/global_antibody

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices